Navigation Links
Cardiac Dimensions® Receives CE Mark Approval for Enhanced CARILLON® Mitral Contour System™
Date:9/29/2011

KIRKLAND, Wash., Sept. 29, 2011 /PRNewswire/ -- Cardiac Dimensions®, Inc. today announced that it has received Conformite Europeenne (CE) Mark approval for a newly enhanced version of its CARILLON® Mitral Contour System™, a novel therapy for treating heart failure patients suffering from functional mitral regurgitation (FMR). Receipt of the CE Mark enables Cardiac Dimensions to initiate a commercial launch of the enhanced device in Europe, which the Company noted will begin in 2012.

The CE Mark approval follows the successful completion of the AMADEUS and TITAN clinical trials of the CARILLON system, which demonstrated significant reduction in FMR and significant improvement in functional capacity and quality of life. An additional trial with the enhanced version of CARILLON, called TITAN II, was recently initiated to further the clinical experience.

"We are delighted to have achieved this critical milestone, which allows us to distribute CARILLON throughout Europe," said Rick Stewart, President and Chief Executive Officer of Cardiac Dimensions. "We believe CARILLON's novel approach to addressing FMR holds significant promise for the millions of heart failure patients who suffer from this debilitating and progressive condition. The CE Mark approval of CARILLON is a reflection of our rapidly growing clinical experience, which suggests that this device is uniquely positioned to reverse the course of heart failure in this largely under-addressed patient population. Also, we are pleased to have the opportunity to further substantiate our initial clinical experiences through the commencement of the TITAN II trial."  

Janusz Lipiecki, M.D., of Clinique Pole Sante Republique in Clermont Ferrand, France, one of the TITAN and TITAN II investigators, commented: "FMR secondary to left ventricular dilatation is associated with poor prognosis and high rates of mortality. As a new treatment option, CARILLON offers compelling and uniq
'/>"/>

SOURCE Cardiac Dimensions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Personalized Medicine - The Genomic Revolution in Cardiac Care
2. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
3. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
4. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
5. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
6. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
7. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
11. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Cardinal Innovations Healthcare Solutions , ... high-touch service delivery, is featuring its highly successful ... National Council for Behavioral Health,s annual National Conference ... 2015, at the Gaylord Palms Resort and Convention ... attracts participants from mental health and addiction treatment ...
(Date:4/20/2015)... 20, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... and drug-delivery therapies, today shared highlights of new ... Cancer Research (AACR) annual meeting. Halozyme also announced ... Phase 2 study in pancreatic cancer, Study 202, ... American Society of Clinical Oncology (ASCO). ...
(Date:4/20/2015)... , April 20, 2015  Published results ... trends in the ability of Neuraltus Pharmaceuticals ... of amyotrophic lateral sclerosis (ALS, also known as ... treatment period. While NP001,s slowing of decline in ... was not statistically significant, clinically meaningful slowing of ...
Breaking Medicine Technology:Cardinal Innovations Highlights its Managed Care Model During National Council for Behavioral Health's Annual Conference 2Cardinal Innovations Highlights its Managed Care Model During National Council for Behavioral Health's Annual Conference 3Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 2Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 3Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 4Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 5Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 2Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 4Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 5
... Pursuant to the filing of a Form 13D with the ... global leader in protection solutions, today announced it has made ... acquired 9.66% of the issued and outstanding shares of common ... manufactures and sells a comprehensive line of safety garments and ...
... SCOLR Pharma, Inc. (OTCQB: SCLR) today announced that ... its extended-release nutritional products based on the Company,s proprietary ... first significant direct retail sales of its nutritional products. ... CEO, said, "Shipment of these initial orders marks an ...
Cached Medicine Technology:SCOLR Pharma, Inc. Announces Initial Shipments of its Nutritional Products 2
(Date:4/20/2015)... Mutare Health, a Strategic Business ... Lawrence Kosinski, MD, MBA, AGAF, to serve as ... a unique combination of medical experience, technical expertise, ... Health team as it continues to develop ... of care in the healthcare environment. He is ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Goodreads is ... Health Insurance: Why It’s Good for You and Your ... Paul Zane Pilzer and Rick Lindquist have released ... Insurance: Why It’s Good for You and Your Company. ... employer health insurance woes - employer-funded individual health insurance. ...
(Date:4/20/2015)... April 20, 2015 Advance Home Care ... personal matter that many customers would prefer not to share ... March 30th a discreet delivery method allowing customers to order ... at their home without fear of a neighbor or passerby ... method is available now on all orders and no minimum ...
(Date:4/20/2015)... Florida Hospital at Connerton Long Term ... from Select Medical, during the annual ceremony hosted at ... Chief Operating Officer, Debi Martoccio, received the Leadership Award ... of six recipients out of 113 hospitals nationwide. The ... for the contributions to the community as well as ...
(Date:4/20/2015)... 1% for the Planet , one of the ... Williams, the network’s Director of Partnerships, will step into the ... been part of 1% for the Planet since early 2014, ... Northern Forest Canoe Trail, a 1% for the Planet nonprofit ... of and advocacy for the outdoors, a commitment which is ...
Breaking Medicine News(10 mins):Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 3Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 3Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 2Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 3Health News:1% for the Planet Announces New CEO 2Health News:1% for the Planet Announces New CEO 3
... , WEDNESDAY, Jan. 5 (HealthDay News) -- Women with ... to have a gene thought to be connected to the ... help researchers gain more insight into the development of MS, ... particularly among women. Although no one knows what causes MS, ...
... Lou Gehrig,s disease, or amyotrophic lateral sclerosis (ALS), ... clumps in brain and spinal-cord cells that include an ... building block of the lesions formed by these clumps. ... Journal of Clinical Investigation , a team led by ...
... are reporting development of a less expensive, more eco-friendly method ... may be a more healthful form of water. Their report ... Research . Changgong Meng and Feng Huang note ... mixture of H2O and tiny amounts of D2O about ...
... of researchers at the Columbia University College of Dental ... key role in vascular pathogenesis, specifically atherosclerosis, or what ... the number one cause of death in the ... in cardiovascular diseases has been challenging because researchers have ...
... maximum temperature of children,s bath water can significantly reduce ... the risk of scalding, according to researchers at The ... partnership with Glasgow Housing Association, found that families with ... and cold water pipes in their bathroom had bath ...
... New Rochelle, NY, January 5, 2011A new, simplified method ... of shuttling genes into host cells will help advance ... into large animal studies and human clinical trials. The ... an article published Instant Online ahead of publication in ...
Cached Medicine News:Health News:Study Sheds Light on Genetic Risk of MS 2Health News:Malfunctioning gene associated with Lou Gehrig's disease leads to nerve-cell death in mice 2Health News:Bacteria eyed for possible role in atherosclerosis 2Health News:Bacteria eyed for possible role in atherosclerosis 3Health News:Thermostatic mixer valves could significantly reduce the risk of scalding in children, study finds 2Health News:Thermostatic mixer valves could significantly reduce the risk of scalding in children, study finds 3Health News:Faster, scalable method for producing AAV-based gene transfer vectors 2
Bio-Rad's Liquichek™ D-dimer Control provides the laboratory with a liquid, trilevel, human plasma based control for the monitoring of D-dimer testing on most automated coagulation, chemistry a...
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek Diabetes Control is a human whole blood based product used to monitor hemoglobin fractions associated with diabetes, including Hemoglobins A1, A1C, F and Total Glycated Hemoglobin....
... Liquichek Qualitative Urine Toxicology Control is a ... rapid urine drug screen panels, including Point ... test kits like Bio-Rad TOX/See, Biosite Triage ... qualitative results (+/) for popular kits and ...
Medicine Products: